Ocugen (OCGN) Competitors $0.93 +0.00 (+0.25%) Closing price 04:00 PM EasternExtended Trading$0.92 0.00 (-0.15%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. CRMD, NAGE, WVE, AUPH, ELVN, ABCL, PAHC, VERV, COLL, and AKBAShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include CorMedix (CRMD), Niagen Bioscience (NAGE), WAVE Life Sciences (WVE), Aurinia Pharmaceuticals (AUPH), Enliven Therapeutics (ELVN), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "pharmaceutical products" industry. Ocugen vs. Its Competitors CorMedix Niagen Bioscience WAVE Life Sciences Aurinia Pharmaceuticals Enliven Therapeutics AbCellera Biologics Phibro Animal Health Verve Therapeutics Collegium Pharmaceutical Akebia Therapeutics Ocugen (NASDAQ:OCGN) and CorMedix (NASDAQ:CRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, risk, dividends, profitability, analyst recommendations, earnings and valuation. Do institutionals & insiders hold more shares of OCGN or CRMD? 10.3% of Ocugen shares are owned by institutional investors. Comparatively, 34.2% of CorMedix shares are owned by institutional investors. 4.3% of Ocugen shares are owned by company insiders. Comparatively, 5.3% of CorMedix shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, OCGN or CRMD? Ocugen has a beta of 4.18, meaning that its share price is 318% more volatile than the S&P 500. Comparatively, CorMedix has a beta of 1.58, meaning that its share price is 58% more volatile than the S&P 500. Do analysts rate OCGN or CRMD? Ocugen presently has a consensus price target of $6.00, suggesting a potential upside of 547.67%. CorMedix has a consensus price target of $17.14, suggesting a potential upside of 47.91%. Given Ocugen's stronger consensus rating and higher possible upside, analysts plainly believe Ocugen is more favorable than CorMedix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ocugen 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media refer more to OCGN or CRMD? In the previous week, CorMedix had 28 more articles in the media than Ocugen. MarketBeat recorded 29 mentions for CorMedix and 1 mentions for Ocugen. Ocugen's average media sentiment score of 0.93 beat CorMedix's score of 0.52 indicating that Ocugen is being referred to more favorably in the media. Company Overall Sentiment Ocugen Positive CorMedix Positive Which has stronger valuation & earnings, OCGN or CRMD? CorMedix has higher revenue and earnings than Ocugen. Ocugen is trading at a lower price-to-earnings ratio than CorMedix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOcugen$4.05M66.80-$54.05M-$0.19-4.88CorMedix$43.47M18.08-$17.93M$0.2252.68 Is OCGN or CRMD more profitable? CorMedix has a net margin of 20.81% compared to Ocugen's net margin of -1,271.12%. CorMedix's return on equity of 22.57% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Ocugen-1,271.12% -223.00% -92.20% CorMedix 20.81%22.57%17.02% SummaryCorMedix beats Ocugen on 12 of the 17 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$270.54M$2.90B$5.49B$8.93BDividend YieldN/A2.69%5.38%4.12%P/E Ratio-4.8821.2626.2019.89Price / Sales66.80279.34415.50166.23Price / CashN/A41.8936.4957.06Price / Book9.267.508.055.39Net Income-$54.05M-$55.05M$3.15B$248.50M7 Day Performance-10.92%2.49%1.92%2.96%1 Month Performance10.65%7.40%4.90%6.02%1 Year Performance-42.46%5.42%35.95%20.44% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.3239 of 5 stars$0.93+0.2%$6.00+547.7%-43.1%$270.54M$4.05M-4.8880CRMDCorMedix2.3566 of 5 stars$16.56+21.7%$15.83-4.4%+175.5%$1.12B$43.47M75.2830Analyst ForecastAnalyst RevisionHigh Trading VolumeNAGENiagen Bioscience1.4962 of 5 stars$13.64+1.5%$19.50+43.0%N/A$1.07B$99.60M80.24120WVEWAVE Life Sciences4.5387 of 5 stars$6.94+5.6%$20.50+195.5%+24.4%$1.07B$108.30M-8.26240Positive NewsAUPHAurinia Pharmaceuticals2.705 of 5 stars$7.83+0.8%$11.50+46.9%+36.2%$1.06B$235.13M27.96300ELVNEnliven Therapeutics2.4624 of 5 stars$20.27-4.8%$39.60+95.4%-13.4%$994.68MN/A-10.5650Analyst ForecastABCLAbCellera Biologics2.2412 of 5 stars$3.33-2.3%$8.33+150.3%+25.5%$993.75M$23.11M-5.95500PAHCPhibro Animal Health3.5439 of 5 stars$24.46+2.4%$20.80-15.0%+56.2%$991.36M$1.02B31.361,940VERVVerve Therapeutics3.4866 of 5 stars$11.11+0.4%$14.75+32.8%+126.5%$989.90M$32.33M-5.26110COLLCollegium Pharmaceutical4.0217 of 5 stars$29.88+0.2%$43.75+46.4%-7.1%$960.10M$664.28M24.49210News CoverageAKBAAkebia Therapeutics4.3274 of 5 stars$3.64-1.1%$6.75+85.4%+259.0%$956.01M$160.18M-17.33430News CoveragePositive NewsInsider Trade Related Companies and Tools Related Companies CorMedix Alternatives Niagen Bioscience Alternatives WAVE Life Sciences Alternatives Aurinia Pharmaceuticals Alternatives Enliven Therapeutics Alternatives AbCellera Biologics Alternatives Phibro Animal Health Alternatives Verve Therapeutics Alternatives Collegium Pharmaceutical Alternatives Akebia Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored“E.I.”- The biggest prediction of my career?One expert predicts that E.I. could see over 200,000% growth... But you need to move fast...Behind the Markets | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCGN Stock Alerts